Advertisement
Advertisement
INBX
Inhibrx Biosciences, Inc. Common Stock
90.61
USDSponsored
-1.13
-1.23%
Nov 10, 15:59 UTC -5
Closed
After-Market
90.89
+0.28
+0.31%
Inhibrx Biosciences, Inc. Common Stock (INBX) Earnings
INBX Earnings Reports
Positive Surprise Ratio
INBX beat 12 of 24 last estimates.
50%
Next Report
In 3 Days
Date of Next Report
Nov 13, 2026
Estimate for Q3 26 (Revenue/ EPS)
--
/-$2.57
Implied change from Q2 26 (Revenue/ EPS)
--
/+9.83%
Implied change from Q3 25 (Revenue/ EPS)
--
/+13.22%
Inhibrx Biosciences, Inc. Common Stock earnings per share and revenue
On Aug 13, 2026, INBX reported earnings of -2.34 USD per share (EPS) for Q2 26, beating the estimate of -2.43 USD, resulting in a 4.01% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -8.91% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 3 analysts forecast an EPS of -2.57 USD, with revenue projected to reach -- USD, implying an increase of 9.83% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kura Oncology, Inc.
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.83
Actual
-$0.78
Surprise
+7.00%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.63
Actual
-$0.73
Surprise
-14.53%
Autolus Therapeutics plc - ADR
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.21
Surprise
-27.20%
Protalix BioTherapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.03
Actual
$0.05
Surprise
+265.02%
PepGen Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-1.19%
Humacyte, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.07
Surprise
+22.91%
Seer, Inc. Class A Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.25
Actual
-$0.25
Surprise
+1.96%
Scholar Rock Holding Corporation Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.86
Actual
-$0.81
Surprise
+6.18%
TELA Bio, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.13
Surprise
+20.54%
Atossa Therapeutics, Inc. Common Stock
Report Date
Nov 10, 2026 For Q3 26
Estimate
-$0.90
Actual
-$0.56
Surprise
+38.31%
FAQ
What were Inhibrx Biosciences, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Inhibrx Biosciences, Inc. Common Stock reported EPS of -$2.34, beating estimates by 4.01%, and revenue of $0.00, 0% as expectations.
How did the market react to Inhibrx Biosciences, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -8.91%, changed from $97.01 before the earnings release to $88.37 the day after.
When is Inhibrx Biosciences, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 13, 2026.
What are the forecasts for Inhibrx Biosciences, Inc. Common Stock's next earnings report?
Based on 3
analysts, Inhibrx Biosciences, Inc. Common Stock is expected to report EPS of -$2.57 and revenue of -- for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.